scholarly article | Q13442814 |
P50 | author | Hawk Kim | Q57840679 |
Yunsuk Choi | Q87433063 | ||
Jae-Cheol Jo | Q89221268 | ||
P2093 | author name string | Young Joo Min | |
Sook-Kyoung Heo | |||
Eui-Kyu Noh | |||
Yoo Kyung Jeong | |||
Jin Ho Baek | |||
SuJin Koh | |||
Jeong Yi Kim | |||
P2860 | cites work | Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review | Q28067339 |
Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass III | Q28186462 | ||
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia | Q28271726 | ||
Targeting the dynamic HSP90 complex in cancer | Q28288602 | ||
Targeting heat shock proteins in cancer | Q28298397 | ||
Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity | Q28539582 | ||
Radotinib Induces Apoptosis of CD11b+ Cells Differentiated from Acute Myeloid Leukemia Cells | Q28548235 | ||
Molecular mechanism and physiological functions of clathrin-mediated endocytosis | Q29615660 | ||
Dynasore, a cell-permeable inhibitor of dynamin | Q29619881 | ||
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts | Q32061790 | ||
Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors | Q33414445 | ||
Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. | Q33848888 | ||
Heat shock protein 90 as a molecular target for cancer therapeutics | Q35099516 | ||
High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia | Q35361598 | ||
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia | Q35528633 | ||
The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine | Q35673943 | ||
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition | Q35760845 | ||
Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells | Q35786902 | ||
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. | Q35952396 | ||
The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents | Q37141899 | ||
Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics | Q37240557 | ||
Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia | Q37386171 | ||
Targeting HSP90 for cancer therapy | Q37463739 | ||
Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications | Q37827283 | ||
The therapeutic target Hsp90 and cancer hallmarks | Q38037753 | ||
Therapeutic targeting of c-KIT in cancer | Q38057806 | ||
Ganetespib and HSP90: translating preclinical hypotheses into clinical promise | Q38189961 | ||
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer | Q38648408 | ||
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | Q38712298 | ||
Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. | Q38754508 | ||
Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer | Q38788166 | ||
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia | Q38989476 | ||
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells | Q39033189 | ||
Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia | Q39061903 | ||
Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation. | Q39245467 | ||
Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias | Q39966770 | ||
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia | Q40719234 | ||
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells | Q42970606 | ||
Inhibition of c-Kit by tyrosine kinase inhibitors | Q43175180 | ||
Dasatinib promotes ATRA-induced differentiation of AML cells | Q43208673 | ||
The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells | Q46614261 | ||
Radotinib induces high cytotoxicity in c-KIT positive acute myeloid leukemia cells | Q47836202 | ||
Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. | Q51068076 | ||
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer. | Q51638544 | ||
HEL Cells: A New Human Erythroleukemia Cell Line with Spontaneous and Induced Globin Expression | Q52831182 | ||
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets | Q55115709 | ||
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells | Q67704489 | ||
Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA | Q70157088 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | acute myeloid leukemia | Q264118 |
dasatinib | Q419940 | ||
radotinib | Q15269680 | ||
dasatinib monohydrate | Q27139135 | ||
P304 | page(s) | 15278 | |
P577 | publication date | 2017-11-10 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death | |
P478 | volume | 7 |